FDA To Release Only Confirmed New Device Risk Data It Sees, Says Final Emerging Signals Guidance
Executive Summary
FDA Dec. 13 issued a final "emerging signals" guidance that includes some significant changes from the draft version released late last year. The update emphasizes that the agency will release to the public only confirmed information that it has seen on adverse events or other negative reports connected to a marketed medical device, which could change the product's risk profile.
You may also be interested in...
What US FDA’s ‘Emerging Signals’ Guidance Means For Medical Device Manufacturers
Thanks to the relatively new agency guidance document related to emerging medical device signals, consumers and health-care providers will receive more prompt and frequent notifications of potential product risks. But there is potential ambiguity for every stakeholder involved, Michael Good of Stericycle ExpertSOLUTIONS explains in this Medtech Insight guest column.
Consumers Groups Praise FDA Draft ‘Emerging Signals’ Plan; Industry Continues Opposition
FDA’s proposed decision to start giving the public early warning of device risks in its “Emerging Signals” draft was praised by consumer and patient groups in March comments, but industry complained that the agency has no authority to issue early warnings. Companies say the communications will confuse patients and gives firms no chance to review the message FDA sends out about product risks.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.